• Lung Cancer Group Cologne
  • Contact
  • Privacy Policy
  • English
    • Deutsch (German)
Netzwerk Genomische Medizin Lungenkrebs
  • Home
  • Health insurance companies
  • General information
  • Privacy Policy
  • Cookie Policy
  • Diagnostics
  • Hybrid-capture
  • Driver mutations
  • Fast-track analysis for first-line treatment
  • Driver mutations in lung cancer
  • Network Genomic Medicine – Lung Cancer
  • New therapeutic approaches from genomic research
  • New immunotherapeutic therapeutic approaches
  • Molecular Diagnostics
  • Contact
  • Imprint
  • Second Opinion service
  • Service invoicing
    • For pathologists
  • Map
  • Clinical trials
    • General information
    • Lung Cancer Study Group
    • What is a clinical trial?
    • Participation in a trial
  • The Network
    • Aims
    • Funding
    • Network Genomic Medicine cancer information system (NGMcis)
    • Publications
    • Related links
    • Our team
  • Ärzte
  • Veranstaltungen
Select Page

Prognostic Impact of [18F]Fluorothymidine and [18F]Fluoro-D-Glucose Baseline Uptakes in Patients with Lung Cancer Treated First-Line with Erlotinib

Scheffler M, Zander T, Nogova L, Kobe C, Kahraman D, Dietlein M, Papachristou I, Heukamp LC, Buettner R, Boellard R, Lammertsma AA, Querings S, Stoelben E, Engel-Riedel W, Neumaier B, Wolf J

Journal: PLoS One
Published: January 2013

  • © 2016-2018 Network Genomic Medicine (NGM)
  • Contact
  • Imprint
  • Privacy Policy

Designed by Elegant Themes | Powered by WordPress